Wedbush Reiterates Outperform Rating on BridgeBio Oncology Therapeutics, In (BBOT)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts BBOT Hot Sheet
Price: $2.66 -6.67%
Rating Summary:
10 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
10 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Wedbush analyst David Nierengarten reiterated an Outperform rating and $25.00 price target on BridgeBio Oncology Therapeutics, In (NASDAQ: BBOT)
For an analyst ratings summary and ratings history on BridgeBio Oncology Therapeutics, In click here. For more ratings news on BridgeBio Oncology Therapeutics, In click here.
Shares of BridgeBio Oncology Therapeutics, In closed at $ yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta's Muse AI to counter China models with subscribers, not ads, Alexandr Wang says - Nikkei
- Honda to sell Mitsubishi Triton-based pickup truck in ASEAN by 2028
- Instacart (CART) Exploring Sale - The Information
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
